vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Finwise Bancorp (FINW). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $42.7M, roughly 2.0× Finwise Bancorp). BillionToOne, Inc. runs the higher net margin — 6.8% vs 6.4%, a 0.4% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Finwise Bancorp is a U.S.-based financial holding company that operates primarily through its community banking subsidiary. It offers a full suite of retail and commercial financial services, including deposit accounts, personal loans, mortgage products, small business financing, and wealth management solutions, serving local retail consumers and small to medium-sized business clients across its regional operating markets.
BLLN vs FINW — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $42.7M |
| Net Profit | $5.7M | $2.7M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | — |
| Net Margin | 6.8% | 6.4% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $42.7M | ||
| Q4 25 | — | $46.9M | ||
| Q3 25 | $83.5M | $36.7M | ||
| Q2 25 | — | $25.1M | ||
| Q1 25 | — | $22.1M | ||
| Q4 24 | — | $21.1M | ||
| Q3 24 | $38.4M | $20.8M | ||
| Q2 24 | — | $19.8M |
| Q1 26 | — | $2.7M | ||
| Q4 25 | — | $3.9M | ||
| Q3 25 | $5.7M | $4.9M | ||
| Q2 25 | — | $4.1M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | $-14.9M | $3.5M | ||
| Q2 24 | — | $3.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 11.7% | ||
| Q3 25 | 11.5% | 17.5% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | 20.1% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | -32.9% | 22.2% | ||
| Q2 24 | — | 21.1% |
| Q1 26 | — | 6.4% | ||
| Q4 25 | — | 8.4% | ||
| Q3 25 | 6.8% | 13.3% | ||
| Q2 25 | — | 16.3% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | -38.8% | 16.6% | ||
| Q2 24 | — | 16.1% |
| Q1 26 | — | $0.20 | ||
| Q4 25 | — | $0.27 | ||
| Q3 25 | $0.10 | $0.34 | ||
| Q2 25 | — | $0.29 | ||
| Q1 25 | — | $0.23 | ||
| Q4 24 | — | $0.19 | ||
| Q3 24 | $-1.47 | $0.25 | ||
| Q2 24 | — | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | — |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $196.6M |
| Total Assets | $327.5M | $899.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $163.4M | ||
| Q3 25 | $195.2M | $105.6M | ||
| Q2 25 | — | $90.1M | ||
| Q1 25 | — | $120.3M | ||
| Q4 24 | — | $109.2M | ||
| Q3 24 | — | $85.8M | ||
| Q2 24 | — | $89.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $196.6M | ||
| Q4 25 | — | $193.2M | ||
| Q3 25 | $-239.5M | $187.8M | ||
| Q2 25 | — | $182.0M | ||
| Q1 25 | — | $177.4M | ||
| Q4 24 | — | $173.7M | ||
| Q3 24 | $-242.9M | $170.4M | ||
| Q2 24 | — | $165.8M |
| Q1 26 | — | $899.4M | ||
| Q4 25 | — | $977.1M | ||
| Q3 25 | $327.5M | $899.9M | ||
| Q2 25 | — | $842.5M | ||
| Q1 25 | — | $804.1M | ||
| Q4 24 | — | $746.0M | ||
| Q3 24 | — | $683.0M | ||
| Q2 24 | — | $617.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-28.4M | ||
| Q3 25 | $13.8M | $3.5M | ||
| Q2 25 | — | $-18.3M | ||
| Q1 25 | — | $-21.6M | ||
| Q4 24 | — | $-15.0M | ||
| Q3 24 | — | $-9.8M | ||
| Q2 24 | — | $-7.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-28.6M | ||
| Q3 25 | $6.5M | $3.4M | ||
| Q2 25 | — | $-19.8M | ||
| Q1 25 | — | $-23.3M | ||
| Q4 24 | — | $-16.1M | ||
| Q3 24 | — | $-13.4M | ||
| Q2 24 | — | $-7.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -61.1% | ||
| Q3 25 | 7.7% | 9.4% | ||
| Q2 25 | — | -79.0% | ||
| Q1 25 | — | -105.3% | ||
| Q4 24 | — | -76.0% | ||
| Q3 24 | — | -64.3% | ||
| Q2 24 | — | -38.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | 8.8% | 0.1% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 17.2% | ||
| Q2 24 | — | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | -7.26× | ||
| Q3 25 | 2.42× | 0.71× | ||
| Q2 25 | — | -4.48× | ||
| Q1 25 | — | -6.78× | ||
| Q4 24 | — | -5.37× | ||
| Q3 24 | — | -2.84× | ||
| Q2 24 | — | -2.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
FINW
| Net Interest Income | $28.1M | 66% |
| Noninterest Income | $14.6M | 34% |
